Drugs Made in America AcquisDMAAU
13F holders, Q4 2025 (December 31)5holders −3
0new positions
3sold out
$10.24avg. 13F price*
At the end of Q4 2025, 5 institutions reported holding Drugs Made in America Acquis (DMAAU) in their 13F filings, down 3 from Q3 2025. 0 opened new positions and 3 sold out. The largest holders were KRYGER CAPITAL Ltd ($3.0M), Wolverine Asset Management LLC ($1.4M) and Clear Street Group Inc. ($957K).
- Company
- Drugs Made in America Acquis
- CUSIP
- G2847J120
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $1.4M |
All 13F filers, Q3 2025 → Q4 2025: 47,546 shares bought and 144,700 shares sold, net −97,154 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| KRYGER CAPITAL Ltd | 0.23% | Add +1.3% | 303,810 | $3.0M |
| Wolverine Asset Management LLC | 0.08% | No change | 130,000 | $1.4M |
| Clear Street Group Inc. | 0.01% | Add +92.1% | 91,219 | $957K |
| Robinson Capital Management, LLC | 0.13% | No change | 30,000 | $315K |
| UBS Group AG | 0.00% | Reduce -56.4% | 8,021 | $84K |
"% of holder's portfolio" is DMAAU's weight in each manager's 13F, not the share of Drugs Made in America Acquis the manager owns.